Handbook of targeted cancer therapy

Handbook of targeted cancer therapy / editors, Daniel D. Karp, Gerald S. Falchook ; assistant editor, Johnique T. Atkins.

Make optimal use of the latest personalized therapeutic strategies with Handbook of Targeted Cancer Therapy! This concise, practical oncology reference examines more than 120 targeted therapy agents for which clinical trial data are available, and explains when and how you can use them to most effec...

Full description

Saved in:
Bibliographic Details
Other Authors: Karp, Daniel D. (Editor), Falchook, Gerald S. (Editor), Atkins, Johnique T. (Editor)
Format: eBook
Language:English
Published: Philadelphia : Wolters Kluwer Health, ©2015.
Edition:1st ed.
Subjects:
Cancer > Chemotherapy > Handbooks, manuals, etc.
Antineoplastic agents > Handbooks, manuals, etc.
Drug targeting > Handbooks, manuals, etc.
Cancer > Molecular aspects > Handbooks, manuals, etc.
HEALTH & FITNESS > Diseases > General.
MEDICAL > Clinical Medicine.
MEDICAL > Diseases.
MEDICAL > Evidence-Based Medicine.
MEDICAL > Internal Medicine.
Antineoplastic agents
Cancer > Chemotherapy
Cancer > Molecular aspects
Drug targeting
Therapie
Immuntherapie
Krebs > Medizin
Onkologie
manuals (instructional materials)
handbooks.
Handbooks and manuals
Handbooks and manuals.
Guides et manuels.
Online Access:Click for online access
Table of Contents:
  • Handbook of Targeted Cancer Therapy; Contributors; Preface; Acknowledgments; Contents; Section 1 Targets by Organ Site; Abbreviations; Adrenocortical Carcinoma; Biliary Tract Adenocarcinoma (Gallbladder, Bile Duct); Bladder Carcinoma (Urothelial Cancer); Brain Tumors; Glioblastoma/Malignant Gliomas; Medulloblastoma; Meningiomas; Other NF-Related Tumors; Breast Cancer; ER/PR+; HER2+; Triple-Negative/Basal/Metaplastic; Cervical Cancer; Colorectal Cancer (Adenocarcinoma); Esophageal Cancer (Squamous Cell); Gastric Cancer/Gastroesophageal Junction (Adenocarcinoma); Head and Neck Cancer.
  • Squamous Cell-OropharynxSalivary Gland; Kidney (Renal Cell) Cancer; Liver Cancer (Hepatocellular); Leukemia; Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Chronic Myeloid Leukemia; Chronic Lymphocytic Leukemia; Myeloproliferative Neoplasm; Lung Cancer (Non-Small Cell); Lymphoma; Melanoma; Multiple Myeloma; Ovarian Cancer; Pancreatic Cancer (Ductal Carcinoma); Prostate Cancer (Adenocarcinoma); Sarcoma (Gastrointestinal Stromal Tumors, GIST); Skin Cancer (Basal Cell); Testicular Cancer (Germ Cell Carcinoma); Thymoma and Thymic Carcinoma; Thyroid Cancer.
  • Papillary and Follicular CarcinomaMedullary Carcinoma; Anaplastic Carcinoma; Uterine (Endometrial) Cancer; Section 2 Carcinogenesis from the Perspective of Targeted Therapy; Section 3 Molecular Targets and Pathways; Angiogenesis; Angiogenesis Regulators; Targeting HIF-1Ü; Receptor Tyrosine Kinases; VEGFR and Targeting VEGFR; FGFR and Targeting FGFR; PDGFR and Targeting PDGFR; TIE Receptors Signaling; TIE Receptors; IGF-1R and Insulin Receptor Signaling; IGF-1R and Insulin Receptor; TGFÜ/Ý Pathway; EGFR Family of Receptors; EGFR Ligands; EGFR Resistant and Sensitive Mutations; EGFR Inhibition.
  • Targeting HER2HGF Receptors: MET; Targeting MET; RET Receptor; Targeting RET; KIT Receptor; ALK Receptor; ALK Alterations; G Protein-Coupled Receptor Pathways; RAS/MAPK Pathway; Targeting RAS; Targeting BRAF Mutations; Targeting MEK and MAPK; PI3K Pathway; Targeting PI3K Mutations; AKT Pathway; Targeting AKT Mutations; PTEN Alterations and TSC Mutations; Targeting mTORC1 Complex; Targeting mTORC2 Complex; JAK/STAT Pathway; Targeting JAK; Hedgehog Signaling Pathway; Notch Pathway; Wnt Pathway; SRC Pathway; NFmB Pathway; Death Receptors and Apoptosis; Cell Cycle Regulation; TP53; RB1.
  • CDKN2A RegulationBRCA; BRCA and PARP; Aurora Kinases; Immunotherapy; Section 4 Targeted Therapy Agents; Abiraterone Acetate (Zytiga); ABT-199; Afatinib Dimaleate (Gilotrif); Afuresertib; Alemtuzumab (Campath-1h); Alisertib; Amg 208 and 337; Apatinib; Axitinib (Inlyta); Anetumab Ravtansine; Bevacizumab (Avastin); BI 811283; Bicalutamide (Casodex/Cosudex); Blinatumomab; BMS-936559; Bortezomib (Velcade); Bosutinib (Bosulif); Brentuximab Vedotin (Adcetris); Brivanib Alaninate; Buparlisib; BYL719; Cabozantinib (Cometriq); Carfilzomib (Kyprolis); Cediranib; Cetuximab (Erbitux); Cixutumumab.

Similar Items